GENSCRIPT BIO News

GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH CORPORATION ANNOUNCES THE EUROPEAN COMMISSION''S APPROVAL OF CARVYKTI FOR SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Apr 22 20:27 ET

GENSCRIPT BIO: FORM OF PROXY FOR 2024 ANNUAL GENERAL MEETING

Apr 22 08:33 ET

GENSCRIPT BIO: PROPOSALS FOR (1) GRANTING OF GENERAL MANDATES TO ISSUE NEW SHARES AND TO REPURCHASE SHARES, (2) RE-ELECTION OF RETIRING DIRECTORS, (3) AMENDMENT OF THE SHARE OPTION SCHEME, (4) AMENDMENT OF THE 2019 RESTRICTED SHARE AWARD SCHEME, (5) AMENDMENT OF THE 2021

Apr 22 08:31 ET

GENSCRIPT BIO: NOTICE OF ANNUAL GENERAL MEETING

Apr 22 08:29 ET

GENSCRIPT BIO: ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023

Apr 22 08:28 ET

GENSCRIPT BIO: ANNUAL REPORT 2023

Apr 22 08:25 ET

GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH CORPORATION ANNOUNCES PRELIMINARY SALES FOR CARVYKTI FOR THE QUARTER ENDED 31 MARCH 2024

Apr 16 07:43 ET

GENSCRIPT BIO: PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES AND ADOPTION OF THE AMENDED MEMORANDUM AND ARTICLES

Apr 12 07:01 ET

GENSCRIPT BIO: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION

Apr 12 06:59 ET

GENSCRIPT BIO: APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGE IN COMPOSITION OF BOARD COMMITTEE

Apr 12 06:57 ET

GENSCRIPT BIO: Nomination Committee -Terms of Reference

Apr 12 06:52 ET

GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH ANNOUNCES THE U.S. FDA''S APPROVAL OF CARVYKTI FOR SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Apr 8 07:43 ET

GENSCRIPT BIO: Next Day Disclosure Return

Apr 2 08:57 ET

GENSCRIPT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Apr 2 07:54 ET

GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH USA INC. ENTERS INTO MASTER MANUFACTURING AND SUPPLY SERVICES AGREEMENT WITH NOVARTIS PHARMACEUTICALS CORPORATION

Apr 1 06:17 ET

GENSCRIPT BIO: Next Day Disclosure Return

Mar 26 00:23 ET

GENSCRIPT BIO: VOLUNTARY ANNOUNCEMENT: LEGEND BIOTECH ANNOUNCES PUBLICATION OF INAUGURAL ESG REPORT

Mar 19 08:40 ET

GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 OF A LISTED SUBSIDIARY - LEGEND BIOTECH CORPORATION

Mar 19 07:36 ET

GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH CORPORATION ANNOUNCES POSITIVE OPINION FROM THE U.S. FDA ODAC FOR CARVYKTI FOR THE EARLIER TREATMENT OF PATIENT WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Mar 17 06:05 ET

GENSCRIPT BIO: GRANT OF RESTRICTED SHARES

Mar 13 10:22 ET